

AMENDED CLAIM SET:

1. (currently amended) A ~~therapeutic or prophylactic~~ method for treating renal disease not caused by diabetes by up-regulating L-FABP (liver-type fatty acid-binding protein), which comprises administering to a patient in need thereof of an agent comprising, as an active ingredient, a compound having activity of peroxisome proliferator-activated receptor (PPAR) agonist and having activity of up-regulating the expression of L-FABP, wherein the renal disease is selected from the group consisting of glomerulonephritis, nephrotic syndrome, focal glomerulosclerosis, immune complex nephropathy, lupus nephritis, drug-induced renal injury, and renal insufficiency.

2. (cancelled).

3. (currently amended) The ~~therapeutic or prophylactic~~ method of claim 1, wherein the renal disease is selected from the group consisting of nephrotic syndrome, focal glomerulosclerosis, and drug-induced renal injury.

4. (currently amended) The ~~therapeutic or prophylactic~~ method according to any one of claims 1, 3, and 6, of claim 1 wherein the compound having activity of PPAR agonist is ~~MCC-555~~ and having activity of up-regulating the expression of L-FABP is 5-[6-(2-fluorobenzyloxy)naphthalene-2-ylmethyl]thiazolidine-2,4-dione.

5. (cancelled).

6. (new) The method of claim 1, wherein the renal disease is focal glomerulosclerosis.